Adjuvant therapy

HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene Signature Benefit from (Neo)adjuvant Chemotherapy (CT): Real World FLEX Study

Publication: SABCS 2025, Presentation ID: PS3-08-17 Authors: Mahtani et Read More

2025-12-16T10:39:58-05:00December 15th, 2025|Adjuvant, Evidence, FLEX, FLEX, Neoadjuvant|

70-Gene Signature High Risk Classification Provides Stronger Prognostic Value Than Histologic Grade in HR+HER2– Early Breast Cancer

Publication: SABCS 2025, Presentation ID: PS5-04-19 Authors: Cobain et Read More

2025-12-15T13:52:56-05:00December 15th, 2025|Adjuvant, Evidence, FLEX, FLEX, Neoadjuvant|

Improved 3-Year IDFS With Anthracycline-Based Therapy for Patients With 70-Gene Signature High 2, Luminal B, HR+HER2- Early-Stage Breast Cancer

Publication: SABCS 2025, Presentation ID: PS2-07-03 Authors: O’Shaugnessy et Read More

2025-12-15T13:50:35-05:00December 15th, 2025|Adjuvant, Evidence, FLEX|

Leveraging Real-World Evidence To Personalize Adjuvant Therapy in HR+/HER2- Early Breast Cancer

Publication: JNCI Cancer Spectrum, 2025, 9(5), pkaf092 Authors: Yael Read More

2025-11-19T15:24:23-05:00October 27th, 2025|Adjuvant, Evidence, FLEX, MINDACT, News|
Go to Top